Rising Prevalence of Anaphylaxis to Drive the Global Auto-Injectors Market

According to the study, the global auto-injectors market is likely to grow significantly during the forecast period, due to increasing prevalence of anaphylaxis, increasing cases with multiple sclerosis, rising geriatric population and high production of biologics. Additionally, increasing healthcare spending and various beneficial features of auto-injectors also contribute to the growth of the overall market. However, high cost of auto-injectors and stringent regulatory requirements are some of the key factors restraining the growth of global auto-injectors market.

Explore Report Description at: https://www.psmarketresearch.com/market-analysis/auto-injectors-market

As per the findings of the research, the prefilled auto-injectors is the larger product category in the global auto-injectors market, primarily due to increasing availability of user friendly prefilled auto-injectors in disposable form. Based on manufacturing design, standardized auto-injector was the larger contributor to the global auto-injectors market in comparison to customized auto-injector in 2016. Anaphylaxis was the largest application for auto-injectors, followed by multiple sclerosis, rheumatoid arthritis and other diseases, in 2016. According to World Allergy Organization (WAO), the prevalence of anaphylaxis ranged from 2% of the population in the US, to 0.1% of the population in Korea, and 0.6% to 1% of the population in Australia.

Globally, the increasing demand for biologics has been playing a key role in the growth of the auto-injectors market. The rapidly increasing burden of anaphylaxis, multiple sclerosis, rheumatoid arthritis and other diseases further compels government organizations and healthcare providers to provide improved facilities for effective disease treatment, leading to rising number of launches of technologically advanced products, globally.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/auto-injectors-market/report-sample

Most of the biologics, such as monoclonal antibodies, anticoagulants, and vaccines are large molecules which need to be administered parenterally to achieve the desired therapeutic effects. The demand for development of injectable biologic therapies is increasing, since many peptides break down too quickly in the stomach and after which they no longer remain useful for treatment. Also, various biologic drugs and vaccines require to be injected directly into the bloodstream. The introduction of biosimilars would enforce the usage of injectable in auto-injectors, and thus the consumption and demand of auto-injectors is expected to increase.

Some of the key players operating in the global auto-injectors market include Mylan N.V., Antares Pharma Inc., Becton, Dickinson & Co., Eli Lilly and Company, Pfizer, Inc., Bayer AG, Novartis International AG, Bristol-Myer Squibb, Novartis AG, Amgen Inc. and Biogen Inc.

Global Advanced Visualization Market Analysis, Size, Share, Development and Forecast to 2023

According to the study, the global advanced visualization market is likely to grow from $1.8 billion in 2016 to $3.8 billion by 2023. Technological advancements, increasing demand for efficient and early diagnosis of diseases, and increasing prevalence of chronic diseases have been driving the growth of the global advanced visualization market. The market is further expected to gain revenue due to increasing geriatric population and incorporation of advanced visualization solutions in mobile devices. Integration of picture archiving and communication system (PACS) and advanced visualization solutions along with the rising demand from developing nations would create ample opportunities for the global advanced visualization vendors.

Explore Report Description at: https://www.psmarketresearch.com/market-analysis/advanced-visualization-market

As per the findings of research, hardware and software held larger share in the global market in 2016, primarily due to increasing installation of advanced visualization hardware and software in healthcare settings. The advanced visualization service market is expected to witness higher growth during the forecast period. The higher growth for services is attributed to the increasing demand for the implementation of advanced visualization solutions and training and education services. Among different type of advanced visualization solutions, enterprise-wide thin client-based solutions held larger share in the global market in 2016, and it is also expected to witness higher growth during the forecast period. Improved data storage capacity, multi-user interface, centralized post-processing solutions, streamlined analysis, and enhanced data transfer capabilities of these solutions is significantly driving the growth of the global enterprise-wide thin client-based solutions market.

Geographically, North America has been the largest market for advanced visualization, with the U.S. being the larger contributor to the regional market as compared to Canada. The key factor driving the North American advanced visualization market are technological advancements, increasing healthcare expenditure, growing geriatric population, improved healthcare infrastructure and growing prevalence of chronic diseases. According to the World Health Organization, approximately 324,000 new cases of lung cancer were diagnosed in North America in 2012, and the number is estimated to reach approximately 541,000 by 2030. The emerging economies in Asia-Pacific, especially China and India, are expected to grow tremendously in future, which is expected to bring the Asia-Pacific market approximately equal to the European market by 2023.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/advanced-visualization-market/report-sample

Key companies in the advanced visualization market are collaborating to offer better advanced visualization solutions. In November 2016, TeraRecon, released an advanced integration between iNtuition with Agfa HealthCare’s Enterprise Imaging 8.1. The combined solution provides single user interface for accessing 2D and advanced 3D applications, bi-directional communication between Agfa and TeraRecon viewers, and multi-series data loading for 3D analysis.

Some of the other key players in the market include General Electric Company, Canon, Inc., Siemens AG, Koninklijke Philips N.V, Fujifilm Holdings Corporation, Carestream Health, Agfa-Gevaert N.V., and Ziosoft.

ER+ Breast Cancer Pipeline Offers Novel Therapeutic Targets For The Treatment Of Breast Cancer

The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates, of which nine products are in Phase III, 16 products in Phase II, 18 products in Phase I, and three products are in Pre-Clinical stage. The development of 14 ER+ breast cancer drug candidates was found to be inactive, and 14 products were discontinued. ER+ breast cancer is the most common type of breast cancer diagnosed and refers to the cancer cells that have receptors on their surface to bind with estrogen. Breast cancer is a syndrome that affects the breast tissues. In breast cancer, cells in the breast grow in an uncontrollable manner and form tumor, which can be felt as a lump or can be viewed under x-ray. Invasion of new therapeutic agents, such as gene therapy, cell therapy and monoclonal antibodies are expected to provide an effective and concrete treatment for the disease, more in the light of the new technologies available.

Access Report Overview: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis

As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route and rest by intravenous route and subcutaneous route. Most of the therapeutic candidates are being developed to be administered by oral route due to high patient compliance.

Several companies are developing ER+ breast cancer drug candidates in different phases. Novartis AG, Syndax Pharmaceuticals, Tesaro, Inc. and others have their ER+ breast cancer drug candidates in Phase III stage of development. Novartis AG has three drug candidates in Phase III stage and two drug candidates in Phase I clinical stage.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis/report-sample

Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., Novartis AG, Ipsen, Syndax Pharmaceuticals, Inc., Tesaro, Inc Astellas Pharma Inc., AstraZeneca plc, and Bayer AG.

IgA Nephropathy Pipeline Analysis, 2017 - Clinical Trials & Results, Collaboration and Other Developments

The study analyzed that the IgA nephropathy pipeline comprises of 12 drug candidates, of which one drug candidate is in Phase III stage, five drug candidates are in Phase II stage and three drug candidates are in Pre-Clinical stage. Also, there are two inactive drug candidates and one discontinued drug candidate. IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in the kidneys. This leads to inflammation that with time hinders the kidney’s ability to filter wastes from blood. IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria and hematuria. IgA nephropathy does not have a specific treatment, and the only treatment available is to delay or prevent end stage renal disease (ESRD). Therefore, combination therapies are being used to slow down the rate of proteinuria and hematuria and the use of various targets including a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS) is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis

As per the findings of the research, around 33.0% of drug candidates of IgA nephropathy pipeline are being developed to be administered by subcutaneous route and 22.0% are being developed to be administered by oral route. Route of administration of around 45.0% drug candidates of IgA nephropathy pipeline is not disclosed.

Many companies are involved in the development of IgA nephropathy pipeline, with their products in different phases. Mallinckrodt plc has its drug candidate in Phase III stage of development. Merck KGaA, Pharmalink AB, Anthera Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc. and Omeros Corporation each have their drug candidates in Phase II stage of development.

Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis/report-sample

Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc., Pharmalink AB, Rigel Pharmaceuticals, Inc., Omeros Corporation, IGAN Biosciences, Inc., Shire plc and Visterra, Inc.

Chronic Obstructive Pulmonary Disease Exhibits Emerging Pipeline with 60+ Drug Candidates

The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates, of which eight drug candidates are in Phase III stage of development, 24 drug candidates are in Phase II stage, nine drug candidates are in Phase I, 22 drug candidates are in Pre-Clinical stage and two drug candidates are in Discovery stage. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis. In this condition, lung cells lose their elasticity and get enlarged, which leads to reduction in the amount of gas exchange in the lungs. Sometimes, it progresses to form cancer, stroke and coronary artery disease.

Explore Report at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis

As per the findings of the research, around 40.0% of the drug candidates of chronic obstructive pulmonary disease pipeline are being developed to be administered by inhalation route, 12.0% are being developed to be administered by oral route, 5.0% are being developed to be administered by subcutaneous route, 3.0% are being developed to be administered by intravenous route, 3.0% are being developed to be administered by another route and 37.0% are being developed to be administered by other routes that are undisclosed.

Many companies are involved in the development of drugs for the chronic obstructive pulmonary disease therapeutics pipeline, with their products in different phases. Chiesi Farmaceutici S.p.A., GlaxoSmithKline plc and AstraZeneca plc have their drug candidates in the Phase III stage of development. Adamis Pharmaceuticals Corporation has two drug candidates in Phase II stage of development. Novartis AG also has two drug candidates in Phase II stage of development. Glenmark Pharmaceuticals Ltd. has two drug candidates in Pre-Clinical stage of development.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis/report-sample

The research also found that various companies have collaborated for the development of chronic obstructive pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co., Ltd. entered into an agreement with AstraZeneca plc for the exclusive rights of benralizumab for the treatment of severe asthma and chronic obstructive pulmonary disease in Asia. In June 2013, AstraZeneca plc acquired Pearl Therapeutics, Inc., which was involved in the development of inhaled small-molecule therapeutics for respiratory disease.

Some of the key players developing drugs for the treatment of chronic obstructive pulmonary disease include AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation, Chiesi Farmaceutici S.p.A., Cytokinetics, Inc., Novartis AG and Theravance Biopharma R & D, Inc.

Oral Mucositis Exhibits Significant Growth in Pipeline with Maximum Drug Candidates in Phase II

The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates, of which one drug candidate is in Phase III stage of development, while seven drug candidates are in Phase II stage, four drug candidates are in Phase I stage, five drug candidates are in Pre-Clinical stage and one drug candidate is in the Discovery stage. Oral mucositis is the most common complication of chemotherapy in cancer patients. It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa.

Access Report Overview: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis

As per the findings of the research, around 39.0% drug candidates of oral mucositis pipeline are being developed to be administered by topical route, 17.0% are being developed to be administered by oral route, 17.0% are being developed to be administered by intravenous route and 5.0% by subcutaneous route. Route of administration of around 22.0% drug candidates of oral mucositis pipeline is not disclosed.

Many companies are involved in the development of drugs for the oral mucositis therapeutics pipeline, with their products in different phases. Daewoong Pharmaceutical Co., Ltd. has its drug candidates in the Phase III stage of development. Cellceutix Corporation, Onxeo S.A. and Novartis AG have their drug candidates in the Phase II stage of development. Galera Therapeutics, Inc. has two drug candidates each in Phase II and Phase I stage of development. Oragenics, Inc. has one drug candidate in Discovery stage of development.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis/report-sample

Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc., Onxeo S.A., Novartis AG, TFS Corporation, Izun Pharmaceuticals Corp., Oragenics, Inc., Wellstat Therapeutics Corporation, Otsuka Holdings Co., Ltd. and Galera Therapeutics, Inc.

Contraceptives Market Size, Share, Development, Growth and Demand Forecast to 2023

The global contraceptives market is growing significantly due to increasing incidences of unwanted pregnancies, increasing prevalence of sexually transmitted diseases and advances in contraception techniques. In addition, government and non-government organizations are funding and supporting programs to encourage contraception. Large unexplored contraceptives market in emerging economies is creating ample opportunities for the global contraceptives market to grow at a considerable rate in the coming years. Several major players in the contraception market are actively involved in the research and new product development for contraception, which could meet the demand of cost effective long term contraception.

Explore Report at: https://www.psmarketresearch.com/market-analysis/contraceptives-market

Contraception is a method used to prevent pregnancy. Several contraceptives, such as hormonal drugs, physical barriers, and advanced contraceptive devices have been developed in order to prevent unwanted pregnancy. Contraceptives also help in preventing sexually transmitted infections. According to a report published by Guttmacher Institute, a non-profit organization working in advance sexual and reproductive health, 213.4 million pregnancies occurred across the globe in 2012, of which 40.0% were unintended. Also, high number of sexually transmitted infection is a major concern across the globe. According to the WHO, in 2013, 35.0 million people lived with HIV/AIDS and 1.5 million people died due to AIDS –related illness worldwide. The organization also reported that an estimated 500 million new curable sexually transmitted infections (including chlamydia, gonorrhoea, syphilis and trichomoniasis only) occur across the globe each year.

The global contraceptives market is categorized as devices and drugs. Based on devices, the contraceptives market is categorized as contraceptive sponges, vaginal rings, contraceptive diaphragms, intrauterine devices (IUDs), subdermal implants, male condoms, female condoms, and others. The IUDs segment is further categorized as hormonal IUDs and copper IUDs. On the basis of drugs, the contraceptive market can be categorized as topical contraceptives, contraceptive injectable, and contraceptive pills. Contraceptive pills lead the global contraceptive drugs market due to its convenience in use and high efficiency in emergency contraception.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/contraceptives-market/toc-sample

Some of the major players operating in the global Contraceptives market are CooperSurgical Inc., Mayer Laboratories Inc., Merck & Co. Inc., Bayer AG, Actavis Inc., Reckitt Benckiser plc, Pfizer Inc., The Female Health Company, Teva Pharmaceutical Industries Ltd.